Comparative Pharmacodynamics of Remifentanil, a New Short Acting Opioid, Gi90291a the Active Metabolite and Alfentanil

A comparison of anaesthesia using remifentanil combined with either isoflurane, enflurane or propofol in patients undergoing gynaecological laparoscopy, varicose vein or arthroscopic surgery

“…R EMIFENTANIL is a highly potent, selective μ‐opioid receptor agonist, belonging to the class of 4‐anilidopiperidine derivatives. It is rapidly metabolised by non‐specific esterases to remifentanil acid that is about 4600 times less potent ( 1, 2). The terminal plasma half‐life of remifentanil is 8–10 min and its context sensitivity, i.e.…”

Remifentanil infusion for cardiac catheterization in children with congenital heart disease

“…Remifentanil is a short‐acting µ‐receptor opioid agonist, chemically related to the synthetic 4‐anilidopiperidine receptor agonists. As a result of the ester linkage in its molecular structure, it is rapidly metabolized by nonspecific blood and tissue esterases to an inactive metabolite (1–3). This metabolism accounts for a context sensitive half‐time of 3.2 and a pharmacodynamic half‐time of 5.4 min after a 3‐h infusion in adult volunteers (4).…”